Short answer
Travere Therapeutics, Inc. (TVTX) filed its Q3 2026 10-Q quarterly report on Nov 2, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $225M (up 36.2% year over year) with net income of −$52M.
Q3 2026 key financials · XBRL
- Revenue
- $225M
- +36.2% YoY · +32.4% QoQ
- Net income
- −$52M
- −303.6% YoY · −50.4% QoQ
- Operating margin
- -30.3%
- EPS (diluted)
- −$0.55
- −289.7% YoY · −44.7% QoQ
Source: XBRL data from the Travere Therapeutics, Inc. (TVTX) Q3 2026 10-Q on SEC EDGAR. USD.
Travere Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $224.6M, up $59.7M YoY, driven by FILSPARI sales of $200.2M vs $90.9M
- Worst product line: Tiopronin sales $20.0M vs $22.3M YoY, down $2.2M
- Operating loss $67.0M vs $24.0M; operating margin -29.8% vs -14.6% YoY
- Cash and securities $471.8M at September 30, 2026 vs $322.8M at December 31, 2025
- Operating cash flow $92.4M vs negative $22.9M; civorebrutinib upfront payment $112.5M and IPR&D expense $113.1M
Risk Factors
- Newly added supply-chain risk: BIOSECURE Act exposure after sparsentan’s primary API supplier joined the June 2026 Section 1260H list
- Most materially updated commercialization risk: FILSPARI FSGS launch followed April 2026 traditional FDA approval, increasing sales-force execution demands
- Regulatory compliance risk: FDA issued a July 28, 2026 untitled letter alleging false or misleading FILSPARI safety and efficacy claims
- Operational risk: Phase 3 HARMONY enrollment restarted in the first quarter of 2026 after manufacturing scale-up delays
- Financial risk: Operations may require additional equity or debt financing, including obligations on the 2029 Notes and 2032 Notes
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Travere Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.